In 2017, a cluster of papers have provided strong evidence in favour of the inflammation hypothesis in cardiovascular disease. From fundamental observations on clonal haematopoiesis to clinical evidence indicating that blocking an inflammatory cytokine mitigates heart disease, 2017 has been a watershed year.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
Basic Research in Cardiology Open Access 10 November 2022
-
Inflammasomes as therapeutic targets in human diseases
Signal Transduction and Targeted Therapy Open Access 02 July 2021
-
The effect of apolipoprotein E polymorphism on serum metabolome – a population-based 10-year follow-up study
Scientific Reports Open Access 24 January 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138, S419–S420 (1999).
Ross, R. Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32814-3 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Swirski, F. From clonal haematopoiesis to the CANTOS trial. Nat Rev Cardiol 15, 79–80 (2018). https://doi.org/10.1038/nrcardio.2017.208
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.208
This article is cited by
-
Clonal haematopoiesis and atherosclerotic cardiovascular disease
Nature Reviews Cardiology (2023)
-
Clonal hematopoiesis and cardiovascular disease: deciphering interconnections
Basic Research in Cardiology (2022)
-
Inflammasomes as therapeutic targets in human diseases
Signal Transduction and Targeted Therapy (2021)
-
Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease
Current Atherosclerosis Reports (2021)
-
The effect of apolipoprotein E polymorphism on serum metabolome – a population-based 10-year follow-up study
Scientific Reports (2019)